OPEN END TURBO BULL - VERTEX PHARMACEUTICALS | Real-time Boerse Frankfurt Warrants 05:30:03 03/06/2024 pm IST | ||
| 11.93 EUR | +4.47% |
|
| 1 month | +73.82% | ||
| 3 months | +16.41% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 11.93 | +4.47% |
| 31/24/31 | 11.42 | +9.39% |
| 30/24/30 | 10.44 | -2.70% |
| 29/24/29 | 10.73 | -3.16% |
| 28/24/28 | 11.08 | -10.50% |
Real-time Boerse Frankfurt Warrants
Last update June 03, 2024 at 05:30 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KH4824 |
| ISIN | DE000KH48240 |
| Date issued | 27/03/2023 |
| Strike | 330.7 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 2.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.38 € |
|---|---|
| Lowest since issue | 1.42 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
455.3
USD
Average target price
463.5
USD
Spread / Average Target
+1.80%
- Stock Market
- Certificates
- Certificat
